Eveninthetraditionalwayofshopping, andretailersandto bargainforthe selectedgoodsisnotan easy task, thetwo sides do notmeet thenetworkona more even moredifficult.
That could put Bristol-Myers Squibb in a weak position, allowing Icahn to bargain for aneven higher price--even though it's unlikely any other big drug maker would want to purchase ImClone given the company's exclusive Erbitux deal with Bristol.